Abstract
We previously developed a B-ALL model from E2a-PBX1 transgenic mice (Bijl et al. Abstract 469 ASH 2003 and paper in preparation). We now exploit this model to identify oncogenic collaborators to E2a-PBX1. To achieve this, 18 newborn E2a-PBX1 transgenic mice and 23 control littermates were intraperitonally injected with MMLV. The occurrence of B-ALL in E2a-PBX1 transgenic animals was significantly accelerated when compared to control littermates (mean survival 162 ± 31 versus 191 ± 50 days, respectively, P=0.03), suggesting the presence of E2a-PBX1 specific collaborators. Inverse PCR was performed on genomic DNA isolated from seven E2a-PBX1 and six control tumors. Seventy-two different retroviral insertion sites were recovered from the tumors. Six common integration sites (CIS) for MMLV were identified; including two novel CIS, i.e. Pde4d, a phosphodiesterase, and a hypothetical phospholipase A930027K05Rik. Strikingly, the Hox a locus was targeted in six of seven E2a-PBX1 tumors, and only one of six control tumors. MMLV integrants in the Hox a locus were detected in a 19kb region located between Hoxa6/Hoxa7 and Hoxa10. Two tumors were targeted twice in this locus. Q-PCR analysis for expression of all Hox a cluster genes identified a significant increase for the Hoxa3 to Hoxa10 genes in the transgenic tumors when compared to the expression in a control MMLV induced B-cell tumor (see table, below). Hoxa7 and Hoxa6 were the most frequently and strongly activated (6/6 and 5/6 transgenic tumors, respectively), showing values of 5700 and 6600 fold over expression in one particular tumor. Interestingly, a Hox a locus insertion in a control tumor (table: last row) did not have any effect on gene activation. In this study we demonstrate a preference for MMLV to target the Hox a locus in an E2a-PBX1context. The resultant gene activation suggests that several members of the Hox a locus are functional collaborators to E2a-PBX1 in the induction of B-cell leukemia.
Fold difference in expression for Hox a cluster genes in Hox a targeted tumors compared to a control tumor.
Insertions . | a3 . | a4 . | a5 . | a6 . | a7 . | a9 . | a10 . |
---|---|---|---|---|---|---|---|
a9/a10 | −1 | 1 | 4 | 3 | 138 | 2 | 4 |
a3 | 17 | 55 | 1067 | 5700 | 6608 | 171 | 62 |
a10 | 3 | 1 | 11 | 98 | 38 | 3 | −4 |
a9/a10 | 1 | −1 | 2 | 21 | 9 | 2 | −2 |
a9/a10 2x | 13 | 6 | 19 | 221 | 191 | 85 | 2 |
a7/a9 + a10 | 8 | 4 | 11 | 66 | 44 | 9 | 149 |
a10 | −2 | −6 | 2 | 2 | −2 | −8 | −5 |
Insertions . | a3 . | a4 . | a5 . | a6 . | a7 . | a9 . | a10 . |
---|---|---|---|---|---|---|---|
a9/a10 | −1 | 1 | 4 | 3 | 138 | 2 | 4 |
a3 | 17 | 55 | 1067 | 5700 | 6608 | 171 | 62 |
a10 | 3 | 1 | 11 | 98 | 38 | 3 | −4 |
a9/a10 | 1 | −1 | 2 | 21 | 9 | 2 | −2 |
a9/a10 2x | 13 | 6 | 19 | 221 | 191 | 85 | 2 |
a7/a9 + a10 | 8 | 4 | 11 | 66 | 44 | 9 | 149 |
a10 | −2 | −6 | 2 | 2 | −2 | −8 | −5 |
Author notes
Corresponding author
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal